Open Access

Renal impact of high‑loading‑dose statin pre‑cardiac catheterization in patients with chronic kidney disease and long‑term statin use

  • Authors:
    • Chang Hou
    • Bo Zheng
    • Xin‑Gang Wang
    • Bin Zhang
    • Qiu‑Ping Shi
    • Ming Chen
  • View Affiliations

  • Published online on: July 10, 2019     https://doi.org/10.3892/etm.2019.7766
  • Pages: 1609-1618
  • Copyright: © Hou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have reported that short‑term statin loading effectively protects statin‑naive patients with mild renal insufficiency from contrast‑induced acute kidney injury (CI‑AKI). The aim of the present study was to determine whether patients with more advanced chronic kidney disease (CKD) and long‑term statin therapy also benefit from high-loading statin pretreatment. A total of 256 consecutive patients with moderate‑to‑severe CKD receiving long‑term statin therapy and undergoing percutaneous coronary intervention (PCI) or coronary artery angiography (CAG) were divided into the statin‑loading group (n=34) and the no statin‑loading group (n=222), depending on whether the respective patient received high‑dose statin within 24 h prior to the intervention. The primary endpoint was the percent change in serum creatinine (SCr) levels. Additional endpoints included absolute change in SCr levels, estimated glomerular filtration rate (eGFR) at 48‑72 h after contrast exposure, incidence rate of CI‑AKI and composite in‑hospital adverse events. The mean SCr decreased from baseline in either of the two groups, and the differences in the percent (P=0.930) and absolute change (P=0.990) in SCr levels were not significant between the two groups. Furthermore, no significant difference in the post‑procedural eGFR was observed between the two groups. The incidence rates of CI‑AKI (2.9 vs. 4.1%, P>0.999) and in‑hospital adverse events (0.0 vs. 3.6%, P=0.602) were also similar between the two groups. Stratified analyses were then performed, which yielded results consistent with the above. Multiple linear regression indicated that the baseline eGFR value and current smoking status were independent factors affecting the post‑procedural eGFR value, while high‑dose statin loading was not. Therefore, statin reloading prior to intervention may not provide any further renal protection or decrease the occurrence of in‑hospital adverse events in patients with moderate‑to‑severe CKD receiving long‑term statin therapy, which warrants validation in prospective trials.

References

1 

Nash K, Hafeez A and Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis. 39:930–936. 2002. View Article : Google Scholar : PubMed/NCBI

2 

McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F and Tumlin J; CIN Consensus Working Panel, : Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 98:5K–13K. 2006. View Article : Google Scholar : PubMed/NCBI

3 

Owen RJ, Hiremath S, Myers A, Fraser-Hill M and Barrett BJ: Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: Update 2012. Can Assoc Radiol J. 65:96–105. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, Kosiborod M, Amin AP, Messenger JC, Rumsfeld JS and Spertus JA: Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: Insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 7:1–9. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, Pichard AD, Satler LF, Wu H and Leon MB: Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv. 52:409–416. 2001. View Article : Google Scholar : PubMed/NCBI

6 

Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N and Bellandi F: Persistent renal damage after contrast-induced acute kidney injury: Incidence, evolution, risk factors and prognosis. Circulation. 125:3099–3107. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Azzalini L, Spagnoli V and Ly HQ: Contrast-induced nephropathy: From pathophysiology to preventive strategies. Can J Cardiol. 32:247–255. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N and Yokoyama M: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 154:87–96. 2001. View Article : Google Scholar : PubMed/NCBI

9 

Bonetti PO, Lerman LO, Napoli C and Lerman A: Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 24:225–248. 2003. View Article : Google Scholar : PubMed/NCBI

10 

Chello M, Goffredo C, Patti G, Candura D, Melfi R, Mastrobuoni S, Di Sciascio G and Covino E: Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg. 28:805–810. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Almuti K, Rimawi R, Spevack D and Ostfeld RJ: Effects of statins beyond lipid lowering: Potential for clinical benefits. Int J Cardiol. 109:7–15. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Ricciardelli B, Donnarumma E, Bianco A, Zabatta MA, et al: Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 126:3008–3016. 2012. View Article : Google Scholar : PubMed/NCBI

13 

McCullough PA, Khambatta S and Jazrawi A: Minimizing the renal toxicity of iodinated contrast. Circulation. 124:1210–1211. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Shehata M and Hamza M: Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: A randomized controlled trial. Cardiovasc Ther. 33:35–41. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, Gan J, Jiang T, Li X, Wang W, et al: Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol. 63:62–70. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Leoncini M, Toso A, Maioli M, Tropeano F, Villani S and Bellandi F: Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol. 63:71–79. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, Montinaro A and Di Sciascio G: Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. Am J Cardiol. 108:1–7. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S and Alemdar R: Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology. 61:711–714. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, Bal U and Ozin B: Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis. 21:750–757. 2010.PubMed/NCBI

20 

Su X, Xie X, Liu L, Lv J, Song F, Perkovic V and Zhang H: Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: A systematic review and bayesian network meta-analysis. Am J Kidney Dis. 69:69–77. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med. 150:604–612. 2009. View Article : Google Scholar : PubMed/NCBI

22 

National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 39 (Suppl 1):S1–S266. 2002.PubMed/NCBI

23 

Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almén T, Aspelin P, Bellin MF, Clement O, et al: Contrast induced nephropathy: Updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 21:2527–2541. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A and Ricciardelli B: Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 40:298–303. 2002. View Article : Google Scholar : PubMed/NCBI

25 

Horn PS, Feng L, Li Y and Pesce AJ: Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem. 47:2137–2145. 2001.PubMed/NCBI

26 

Jo SH, Hahn JY, Lee SY, Kim HJ, Song YB, Choi JH, Choi SH, Lee SH and Gwon HC: High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention. J Cardiovasc Med (Hagerstown). 16:213–219. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Abaci O, Arat Ozkan A, Kocas C, Cetinkal G, Sukru Karaca O, Baydar O, Kaya A and Gurmen T: Impact of rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol. 115:867–871. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Galal H, Nammas W and Samir A: Impact of high dose versus low dose atorvastatin on contrast induced nephropathy in diabetic patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Egypt Heart J. 67:329–336. 2015. View Article : Google Scholar

29 

Bidram P, Roghani F, Sanei H, Hedayati Z, Golabchi A, Mousavi M, Hajiannejad A, Pourheidar B, Badalabadi MM, Gharaati M, et al: Atorvastatin and prevention of contrast induced nephropathy following coronary angiography. J Res Med Sci. 20:1–6. 2015.PubMed/NCBI

30 

Rear R, Bell RM and Hausenloy DJ: Contrast-induced nephropathy following angiography and cardiac interventions. Heart. 102:638–648. 2016. View Article : Google Scholar : PubMed/NCBI

31 

Attallah N, Yassine L, Musial J, Yee J and Fisher K: The potential role of statins in contrast nephropathy. Clin Nephrol. 62:273–278. 2004. View Article : Google Scholar : PubMed/NCBI

32 

Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ and Moscucci M: Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med. 118:843–849. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW and Di Sciascio G: Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol. 101:279–285. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M, Sugiura T and Iwasaka T: Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol. 54:192–198. 2009. View Article : Google Scholar : PubMed/NCBI

35 

Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, et al: Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J. 155:499 e1–e8. 2008. View Article : Google Scholar

36 

Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M and Bellandi F: Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 105:288–292. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Hall WD: Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci. 317:176–182. 1999. View Article : Google Scholar : PubMed/NCBI

38 

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H and Wang H: Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: A systematic review and meta-analysis. Eur Heart J. 34:1807–1817. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ, Nassif D, Lopez JJ and Saucedo JF; EVENT Investigators, : In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: A report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2:37–45. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Natsuaki M, Furukawa Y, Morimoto T, Sakata R and Kimura T; CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators, : Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 110:1568–1577. 2012. View Article : Google Scholar : PubMed/NCBI

41 

Dasari TW, Cohen DJ, Kleiman NS, Keyes MJ, Yen CH, Hanna EB and Saucedo JF: Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). Am J Cardiol. 113:621–625. 2014. View Article : Google Scholar : PubMed/NCBI

42 

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 63:2889–2934. 2014. View Article : Google Scholar : PubMed/NCBI

43 

Downs JR and O'Malley PG: Management of dyslipidemia for cardiovascular disease risk reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 163:291–297. 2015. View Article : Google Scholar : PubMed/NCBI

44 

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, et al: National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary. J Clin Lipidol. 8:473–488. 2014. View Article : Google Scholar : PubMed/NCBI

45 

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, et al: 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 37:2999–3058. 2016. View Article : Google Scholar : PubMed/NCBI

46 

McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC and Mehta A: Contrast-induced acute kidney injury. J Am Coll Cardiol. 68:1465–1473. 2016. View Article : Google Scholar : PubMed/NCBI

47 

Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 124:2574–2609. 2011. View Article : Google Scholar : PubMed/NCBI

48 

Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, et al: 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 46:517–592. 2014. View Article : Google Scholar : PubMed/NCBI

49 

Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, Sandberg KR and McCullough PA: Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol. 15:349–354. 2002. View Article : Google Scholar : PubMed/NCBI

50 

Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, Castaldo D, De Micco F, Ricciardelli B and Colombo A: Cystatin C and contrast-induced acute kidney injury. Circulation. 121:2117–2122. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hou, C., Zheng, B., Wang, X., Zhang, B., Shi, Q., & Chen, M. (2019). Renal impact of high‑loading‑dose statin pre‑cardiac catheterization in patients with chronic kidney disease and long‑term statin use. Experimental and Therapeutic Medicine, 18, 1609-1618. https://doi.org/10.3892/etm.2019.7766
MLA
Hou, C., Zheng, B., Wang, X., Zhang, B., Shi, Q., Chen, M."Renal impact of high‑loading‑dose statin pre‑cardiac catheterization in patients with chronic kidney disease and long‑term statin use". Experimental and Therapeutic Medicine 18.3 (2019): 1609-1618.
Chicago
Hou, C., Zheng, B., Wang, X., Zhang, B., Shi, Q., Chen, M."Renal impact of high‑loading‑dose statin pre‑cardiac catheterization in patients with chronic kidney disease and long‑term statin use". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1609-1618. https://doi.org/10.3892/etm.2019.7766